Atropi[INVESTIGATOR_545798], 0.01% and 0.02%  
Vyluma Inc., an affilia te of Nevakar Inc. 
CP-NVK002-0001(5) 14 Jun 2021 IND 130341 
 
CONFIDENTIAL AND PROPRIETARY  Page 1 of 116 CLINICAL TRIAL PROTOCOL 
CP-NVK002-0001 
 
CHILDHOOD ATROPI[INVESTIGATOR_545799] (CHAMP): A 3-ARM RANDOMIZED, 
DOUBLE-MASKED, PLACEBO-CONTROLLED, 
PHASE 3 STUDY OF ATROPI[INVESTIGATOR_545800] 0.01% AND 0.02% 
EudraCT Number: 2018-001077-24 
Study Phase: Phase [ADDRESS_714355] Name: [CONTACT_413323][INVESTIGATOR_370015] O phthalmic Solution 
Indication: Slowing the progression of  myopia in children 
Sponsor: Vyluma Inc., an affiliate of Nevakar Inc. 
NJ Center of Excellence 
1019 Route 202/206, Bldg. K 
Bridgewater, NJ [ZIP_CODE] 
Original Protocol: 01 July 2017  
Protocol Amendment (1): 05 September 2017 
Protocol Amendment (2): 10 April 2018 
Protocol Amendment (3): [ADDRESS_714356] 2019 
Protocol Amendment (4): 09 October 2020 
Protocol Amendment (5): 14 June 2021 
 
CONFIDENTIAL  
The information contained in thi s document is confidential and proprietary property of Vyluma 
Inc., an affiliate of Nevakar Inc . Neither this document nor th e information contained herein may 
be divulged, transmitted, reproduc ed, published, or otherwise u sed by [CONTACT_545822] ., an affiliate of Nevakar Inc.   
Atropi[INVESTIGATOR_545798], 0.01% and 0.02%  
Vyluma Inc., an affilia te of Nevakar Inc. 
CP-NVK002-0001(5) 14 Jun 2021 IND 130341 
 
CONFIDENTIAL AND PROPRIETARY  Page 5 of 116 1. SYNOPSIS 
Name [CONTACT_790]/Company: Vyluma Inc., an affiliate of Nevakar Inc.  
Protocol Number:  CP-NVK002-[ADDRESS_714357] Number: 2018-001077-[ADDRESS_714358]: Atropi[INVESTIGATOR_545801]: Atropi[INVESTIGATOR_52339] 0.01% and 0.02% 
Title of Study: Childhood Atropi[INVESTIGATOR_545802] (CHAMP): A 3-Arm Rand omized, 
Double-Masked, Placebo-Controlled, Phase 3 Study of Atropi[INVESTIGATOR_545803] 
0.01% and 0.02%.  
Study Center(s): 15 â€“ 30 centers in North America, Europe, and [LOCATION_008]. 
Studied Period (Years):  
Estimated date first subject enrolled: November 2017 
Estimated date completion BLEOS Month 36: August [ADDRESS_714359] completed Month 36-  EOS Month 48: Septe mber 2023 Phase of 
development:  
3 
Objective:  Primary: To evaluate the safety and efficacy of 2 concentrations of Atro pi[INVESTIGATOR_413242] (0.01% and 0.02%) compared to Vehicle (placebo) for sl owing the progression of myopia 
in children over a 3-year treatment period. 
Exploratory:  To observe safety and efficacy in subjects re-randomized to 1 year of treatment with 
Atropi[INVESTIGATOR_413202], 0.01% or 0.02%, or Vehicl e following 3 years of treatment 
in children with progressive myopia. 
Study Rationale:  
Vyluma Inc., an affiliate of Nevakar Inc., hereinafter referred  to as the Sponsor, is pursuing the 
development of Atropi[INVESTIGATOR_545804].  
Ametropia in children is common, and if left uncorrected causes  decreased vision, visual discomfort 
(eye strain), strabismus, and/ or amblyopia (AAPOS 2013). The mo st common form of refractive 
error is myopia (nearsightedness), which has its onset in child ren 6 to 12 years of age 
(Zadnik 2015). 
Study Population:  
Study subjects will be childre QPDOHRUIHPDOHDJHGWRÂ”\HDUVDWWKHWLPHRIHQUROO PHQW
with myopia spherical equivalent refraction (SER) of at least - 0.50 D and no greater than -6.00 D in 
each eye, astigmatism of no more than -1.50 D in each eye, and anisometropia (SER) of < 1.50 D as 
measured by [CONTACT_545823]. 
Methodology:  
This will be a 3-arm randomized, multicenter, double-masked, pl acebo-controlled study conducted 
in 2 stages. Stage 1 is a safety and efficacy phase of 3 years (36 months) in duration, during which 
subjects will be allocated to 1 of 3 study medications. Stage 2  is a randomized cross-over phase of 
1 year (12 months) in duration, during which subjects will be r e-randomized to receive 1 of the 3 
study medications with subjects initially randomized to Vehicle  only eligible for randomization to 
Atropi[INVESTIGATOR_545798], 0.01% and 0.02%  
Vyluma Inc., an affilia te of Nevakar Inc. 
CP-NVK002-0001(5) 14 Jun 2021 IND 130341 
 
CONFIDENTIAL AND PROPRIETARY  Page 6 of 116 RUDWURSLQH6XEMHFWVDJHGWRÂ”\HDUVZLOO  enter the study with myopia SER of 
at least -0.50 D and no greater than -6.00 D in each eye as mea sured by [CONTACT_545823]. 
At screening/baseline (Day 0), the site will obtain signed info rmed consent from the parent or legal 
guardian of the subject and assent from the subject (as applica ble). The subject will then undergo a 
screening evaluation to determine eligibility for the study as per the inclusion and exclusion criteria 
defined in the protocol. Following confirmation of eligibility,  the clinical site will access the 
Interactive Response Technology (IRT), which will assign the su bject to 1 of the 3 treatment arms 
and assign the initial study medication kit to be dispensed to the parent/guardian following 
instruction on administration. The allocated study medication w ill be administered, one drop in each 
eye once daily (QD), at bedtime, for 3 years. 
Treatment arms are: 
x Atropi[INVESTIGATOR_413202], 0.01% 
x Atropi[INVESTIGATOR_413202], 0.02% 
x Vehicle (placebo) 
Both eyes will be treated; myopia must be bilateral to qualify.  If myopia is unilateral at screening or 
the child seems likely to cross the threshold for bilateral myo pia of at least -0.[ADDRESS_714360] 
can be asked to return while the enrollment period is still ope n to determine his or her eligibility. 
Subjects will return to the clinical site at 6-month intervals for 3 years to undergo a series of safety 
and efficacy evaluations and at  3-month intervals throughout th e study for update of concomitant 
medications and adverse event (AE) assessment. While it is pref erred that the subject attend every 
visit, the parent/guardian may attend a 3-month visit without t he subject if necessary; both the 
subject and their parent/guardian must be present for all 6-mon th visits. At each study visit, 
unopened/unused and used study medication materials will be ret urned, concomitant medications 
will be updated, AE assessment will be conducted, allocated stu dy medication will be dispensed for 
the next 3-month study period, and treatment adherence assessme nt will be performed. 
Site staff will also contact [CONTACT_545824]/guardian s by [CONTACT_545825] [ADDRESS_714361] completes all safety and efficacy assessments a t Month 36 (the primary efficacy time 
point) the randomized cross-over stage (Stage 2) will commence,  and each subject will be re 
randomized to receive 1 of the 3 study medications for the fina l year of the study. Subjects 
randomized to either 0.01% or 0.02% Atropi[INVESTIGATOR_545805] 1 will be 
re randomized to treatment with Atropi[INVESTIGATOR_545806], 0.01%, Atropi[INVESTIGATOR_545807], 0.02%, or Vehicle, and subjects randomized  to the Vehicle group in Stage 1 
will be re-randomized to active treatment with Atropi[INVESTIGATOR_545808], 0.01% or 
Atropi[INVESTIGATOR_413202], 0.02%. In Stage 2, study medication will be administered 
one drop in each eye QD at bedtime, as before, for [ADDRESS_714362] and their parents/guardians will ag ain return at 6-month intervals for 
safety and efficacy evaluations and at 3-month intervals for up date of concomitant medications and 
AE assessment. As in Stage 1, both the subject and their parent /guardian must be present for all 6-
month visits, but the parent/guardian may attend a 3-month visi t without the subject if necessary. At 
each study visit, unopened/unused and used study medication mat erials will be returned, 
concomitant medications will be updated, AE assessment will be conducted, study medication will 
be dispensed for the next 3-month study period, and treatment a dherence assessment will be 
Atropi[INVESTIGATOR_545798], 0.01% and 0.02%  
Vyluma Inc., an affilia te of Nevakar Inc. 
CP-NVK002-0001(5) [ADDRESS_714363] or their parent/guardian will be encouraged to record t heir dosing on a daily basis, starting 
from the same evening after completing their Month [ADDRESS_714364] visit (Stage 2 of the study) 
in an electronic patient diary (e-diary). The subject or their parent/guardian will be encouraged to 
use their cell phone to upload e-diary responses. At Month [ADDRESS_714365] or their 
parent/guardian do not have a cell phone or are unwilling to us e their cell phone, a device will be 
provisioned by [CONTACT_545826]. Once the i nstillation of the eye drops has been 
successfully completed, subject or their parent/guardian will l og into the application to record 
dosing of the left eye and the right eye and complete diary sub mission daily. The diary can be 
completed between 6:00 PM and 11:[ADDRESS_714366] or their  parent/guardian do not complete 
the e-diary within the allotted time, they will not be able to enter the missing data retroactively, as 
the purpose is to collect information on the actual date the st udy drops were instilled. Once data is 
submitted, this information will be automatically entered into the studyâ€™s Medidata Rave database. 
Inclusion of the Modified Amblyop ia Treatment Index (ATI), qual ity of life (QoL) 
questionnaire 
At Month 42 and Month 48, in addition to other assessments, the  study staff will encourage 
participation in the Modified Amblyopia Treatment Index (ATI), quality of life (QoL) questionnaire 
which has been added to the study to be completed by [CONTACT_70579] t and their parent/guardian. 
Participation is voluntary and will be documented. The parent/g uardian questionnaire should be 
completed prior to the subjectâ€™s questionnaire. The questionnai res should be completed prior to the 
Investigatorâ€™s examination of the subject. 
All subjects are to be re-consented/re-assented at their next s tudy visit, including subjects 
completing an End of Study (EOS) Visit (Stage 1 â€“ Month 36, Mon th 39, Month 42, Month 45, and 
Month 48). 
Number of Subjects (Planned): Subjects will be randomized in a 2:2:3 ratio of vehicle: Atropi [INVESTIGATOR_545809], 0.01%: Atropi[INVESTIGATOR_545810], 0.02% 
The target number of subjects to be randomized into the 6- to 1 0-year age group (436), the primary 
efficacy population, will be: 
x Vehicle (placebo):         125 
x Atropi[INVESTIGATOR_413202], 0.01%:  125 
x Atropi[INVESTIGATOR_413202], 0.02%: 186 
Approximately 483 subjects over all eligible ages will be enrol led, resulting in the following 
numbers of subjects in each arm: 
x Vehicle (placebo):         138 
x Atropi[INVESTIGATOR_413202], 0.01%:  138 
x Atropi[INVESTIGATOR_413202], 0.02%:  [ADDRESS_714367] a sample size re-estimation based on a masked assessment of the primary 
endpoint response rate and/or the subject discontinuation rate.  
The randomization will be stratified twice: (1) by [CONTACT_545827] (subjects < 9 years; subjects 
Â•\HDUVDQGE\UHIUDFWLYHHUURUOHVVP\RSLF6(5 -0.50 to -3.00 D; more myopic: one or 
more eyes with SER-3.01 to -6.00 D). The stratification is used  to balance these characteristics 
across the [ADDRESS_714368] been ran domized. Enrollment may be closed 
Atropi[INVESTIGATOR_545798], 0.01% and 0.02%  
Vyluma Inc., an affilia te of Nevakar Inc. 
CP-NVK002-0001(5) 14 Jun 2021 IND 130341 
 
CONFIDENTIAL AND PROPRIETARY  Page 8 of 116 WRVXEMHFWVDJHÂ•\HDUVIROOR wing enrollment of 50 subjects into this age group to avoid 
over-enrollment into the study.  
The drop-out rate over the 3 years of the safety and efficacy s tage of the study (Stage 1) is estimated 
to be 27% (~10% per year). As l ong as this drop-out rate is not  exceeded, then at least 150 subjects 
(300 eyes) receiving the higher concentration (0.02% atropi[INVESTIGATOR_050]) will be available for the evaluation 
of safety. 
Diagnosis and Main Criteria for Inclusion:  
Inclusion Criteria 
1. Children (male or female) aged 3 to Â”17.[ADDRESS_714369] -0.50 D and no greater than -6.00 D myop ia in each eye as 
measured by [CONTACT_545823]. 
3. If present, astigmatism of no more than -1.50 D in each eye as measured by [CONTACT_545828]. 
4. Anisometropia SER of < 1.50 D as measured by [CONTACT_545829]. 
5. Normal intraocular pressure  of < [ADDRESS_714370] 0.1 logMAR or 20/25 Sne llen equivalent in each eye. 
7. Female subjects of childbearing potential (post menarche) must have a negative urine 
pregnancy test at screening.  
8. Subjectâ€™s parent or legal guardian must provide informed consen t on behalf of the subject, 
and the subject should provide assent when applicable, per Inst itutional Review Board 
(IRB)/Ethics Committee (EC) guidelines. If a subject becomes an  adult (depending on 
country regulations) during the study, they will need to sign a n informed consent form to 
continue in the study. 
Atropi[INVESTIGATOR_545798], 0.01% and 0.02%  
Vyluma Inc., an affilia te of Nevakar Inc. 
CP-NVK002-0001(5) [ADDRESS_714371] strabismus includin g intermittent tropia. 
3. Heart rate is persistently (for more than 10 minutes) > 120 bea ts per minute at 
screening/baseline. 
4. History of any disease or syndrome that predisposes the subject  to severe myopia 
(e.g., Marfan syndrome, Stickler syndrome, retinopathy of prema turity). 
5. History in either eye of abnormal ocular refractive anatomy (e. g., keratoconus, lenticonus, 
spherophakia). 
6. History in either eye of previous intraocular or ocular laser/n on-laser surgery. 
7. Current or history of glaucoma; anatomic narrow anterior chambe r angles. 
8. Serious systemic illness that, in the Investigatorâ€™s opi[INVESTIGATOR_1649], w ould render the subject 
ineligible. 
9. Chronic use of any topi[INVESTIGATOR_545811]/anticholi nergic medications 
(e.g.,atropi[INVESTIGATOR_050], scopolamine, tropi[INVESTIGATOR_31424]) within 21 days prior to screening, and/or 
anticipated need for chronic use during the study period (i.e.,  more than 7 consecutive days 
in 1 month or more than 30 total days in 1 year). (Use of cyclo plegic drops for dilated 
ocular exam are allowable.) 
10. Chronic use (more than 3 days per week) of any topi[INVESTIGATOR_545812] (prescribed 
or over-the-counter) other than the assigned study medication. Use of artificial tears is 
allowed but may not be used within 2 hours of administration of  study medication. 
11. The anticipated need to use chronic ophthalmic or systemic oral  corticosteroids during the 
study. Intranasal, inhaled, topi[INVESTIGATOR_545813], intra-articul ar, perianal steroids, and 
short-term oral steroids (i.e., < 2 weeks) are permitted.  
12. Prior myopia control treatment including orthokeratology, bifoc al contact [CONTACT_13276], or 
progressive addition spectacle lenses. The only allowable prior  treatments are myopic 
correction in the form of single-vision eyeglasses and/or singl e-vision or toric soft contact 
[CONTACT_13276].  
13. Preplanned hospi[INVESTIGATOR_316671] t he study period. (Note: The study period begins at the 
time of randomization.) 
14. Unwilling or unable to complete study procedures or to be follo wed up for the 48-month 
duration of the study. 
15. Participation in any other study of investigational therapy dur ing the study period or within 
the last 30 days. 
16. History of any substance abuse (excessive or habitual use of al cohol and/or drug including 
nicotine) and not willing to abstain from these substance(s) du ring the 4-year study period.  
17. Female subjects who are pregnant, nursing, or plan to become pr egnant at any time during 
the study.  
18. Employees of the study site and their family members are not pe rmitted to participate as 
subjects in the study. Immediate family is defined as a spouse,  parent, child, or sibling, 
whether biological or legally adopted.    
19. Current or history of significant or severe damage to the corne a. 
 
Atropi[INVESTIGATOR_545798], 0.01% and 0.02%  
Vyluma Inc., an affilia te of Nevakar Inc. 
CP-NVK002-0001(5) [ADDRESS_714372], Dosage and Mode of Administration:  
Atropi[INVESTIGATOR_413202], 0.01% or 0.02%, dosed QD by [CONTACT_12523][INVESTIGATOR_545814], at bedtime. 
Reference Therapy, Dosage and Mode of Administration:  
Vehicle (placebo) ophthalmic solution, dosed QD by [CONTACT_12523][INVESTIGATOR_545815], at 
bedtime. 
Duration of Treatment:  
The study will be conducted in 2 stages. Stage 1 is the primary  safety and efficacy stage of the study 
and will be 3 years (36 months) in duration. Subjects will be r andomized in a 2:2:3 ratio of Vehicle: 
Atropi[INVESTIGATOR_413202], 0.01%: Atropi[INVESTIGATOR_370015] O phthalmic Solution, 0.02%. On 
completion of 3 years of treatment, Stage 2, a randomized cross -over stage will commence, and all 
subjects will be re-randomized to 1 of the 3 study medications and will receive this treatment for 
1 year (12 months). Subjects who were randomized to 0.01% or 0. 02% Atropi[INVESTIGATOR_545816] 1 will be re-randomized in a 1 :1:1 ratio to one of the 3 treatment 
arms (Vehicle: Atropi[INVESTIGATOR_413202], 0.01%: Atr opi[INVESTIGATOR_413242], 0.02%), and subjects who were randomized to Vehicle d uring Stage 1 will be re-
randomized in a 1:1 ratio to active treatment (Atropi[INVESTIGATOR_545808], 
0.01%: Atropi[INVESTIGATOR_413202], 0.02%). 
Study Procedures : 
Office Visits should occur within Â± 2 weeks of the expected vis it date.  
Screening/Randomization/Baseline Visit (Day 0):  Sites should complete 
screening/randomization/baseline procedures and enroll subjects  within [ADDRESS_714373] (as applicable). The subject will t hen undergo screening evaluations to 
determine eligibility for the study which will include review o f medical/ocular and prior medication 
history, a urine pregnancy test for female subjects of childbea ring potential, heart rate (HR), 
monocular Best-Corrected Visual Acuity (BCVA) measurement at di stance and near, photopic pupil 
size measurement, slit-lamp examination (SLE) (check for narrow  angles), tonometry, dilated 
fundus examination and cycloplegic autorefraction. Height and w eight will also be assessed.  
Following confirmation of eligibility, the clinical site will m easure axial length and, if possible, 
crystalline lens thickness. The site will access the IRT, which  will assign the subject to 1 of the 
3 treatment arms and assign the initial study medication kit to  be dispensed to the parent/guardian 
following instruction on administration. 
One (1) drop of the study medication will be administered into each eye QD, at bedtime. Because 
AEs are to be collected beginning after signing of informed con sent/assent, the site will document 
any events that may be volunteered spontaneously by [CONTACT_456022]/guardian that occur 
before the end of the visit.  
If the subject requires initial or new spectacles/contact [CONTACT_126107] s (applicable if the refraction reveals at 
least -0.50 D myopic progression and/or if the eye care practit ioner deems it clinically necessary to 
improve vision), the site will provide a refractive prescriptio n and lenses/frames (if needed) or soft 
contact [CONTACT_13276]. 
All screening evaluations will serve as baseline measurements. 
 
Atropi[INVESTIGATOR_545798], 0.01% and 0.02%  
Vyluma Inc., an affilia te of Nevakar Inc. 
CP-NVK002-0001(5) 14 Jun 2021 IND 130341 
 
CONFIDENTIAL AND PROPRIETARY  Page 11 of 116 Stage 1 Telephone Checks â€“ (Months 1, 2, 4.5, 7.5, and 10.5):  Sites will contact [CONTACT_545830]/guardian by [CONTACT_545825] [ADDRESS_714374] 
with maintaining protocol and treatment adherence. 
 
Stage 1 Three-Month Visits (Months 3, 9, 15, 21, 27, and 33) 
At these visits, the subject and their parent/guardian will ret urn to the study site with their 
randomized study medication for an evaluation of treatment adhe rence. While it is preferred that the 
subject attend every visit, the parent/guardian may attend a 3- month visit without the subject if 
necessary. Sites will update concomitant medications, conduct A E assessment, dispense study 
medication, and perform treatment adherence assessment (i.e., s tudy medication accountability). 
(Note: Enrolled subjects approved by [CONTACT_545831] a new site, who reside 
greater than [ADDRESS_714375]â€™s family in order to 
dispense study medication. Assessments may be obtained remotely  via telephone and treatment 
adherence assessments completed at 6-Month interval visits). 
 
Stage 1 Six-Month Visits (Months 6, 12, 18, 24, and 30)  
At these visits, subject and their parent/guardian will return to the study site with their randomized 
study medication for an evaluation of treatment adherence. Subj ects will undergo a measurement of 
height (yearly), weight (yearly) , HR, BCVA measurement (distanc e and near), photopic pupil size 
measurement, SLE, tonometry, dilated fundus examination (yearly ), cycloplegic autorefraction, 
axial length and, if possible, crystalline lens thickness. Site s will update concomitant medications, 
conduct AE assessment, dispense study medication, and perform t reatment adherence assessment. 
 
End of Stage 1/End of Study (EO S) Month 36 Primary Efficacy  (B L-Month 36) and 
Evaluation/Commencement of Stage  2: Randomized Cross-Over (EOS Month 36) 
At the Month 36 visit, End of Stu dy (EOS) visit Stage 1, the su bject and their parent/guardian will 
return to the study site for the EOS Month 36 study visit (Stag e 1). The subject and their 
parent/guardian will return to the study site with their random ized study medication.  
Subjects will undergo a measureme nt of height, weight, HR, BCVA  measurement (distance and 
near), photopic pupil size measurement, SLE, tonometry, dilated  fundus examination, cycloplegic 
autorefraction, axial length and, if possible, crystalline lens  thickness. Subjects will then be re-
randomized. Sites will update concomitant medications, conduct AE assessment, dispense 
randomized study medication for the randomized cross-over stage  (Stage 2), and perform treatment 
adherence assessment. Additionally, the site staff will install  an electronic diary application on 
subjectâ€™s or their parentâ€™s/guardianâ€™s phone. Subject or their parent/guardian will be encouraged to 
record their dosing on a daily basis, starting from the same ev ening after completing their Month [ADDRESS_714376] or their parent/guardian do not have a ce ll phone or are unwilling to use their cell 
phone, a device will be provisioned by [CONTACT_545832]. Electronic diary 
training and Medidata patient cloud electronic clinical outcome  assessments (eCOA) support will be 
provided. 
 
 
 
Atropi[INVESTIGATOR_545798], 0.01% and 0.02%  
Vyluma Inc., an affilia te of Nevakar Inc. 
CP-NVK002-0001(5) 14 Jun 2021 IND 130341 
 
CONFIDENTIAL AND PROPRIETARY  Page 12 of 116 Stage 2 Three-Month Visits (Months 39 and 45) 
The subject and their parent/guardian will return to the study site with their randomized study 
medication for an evaluation of treatment adherence (as in Stag e 1, it is preferred that the subject 
attend every visit, but the parent/guardian may attend a 3-mont h visit without the subject if 
necessary). Sites will update concomitant medications, conduct AE assessment, dispense study 
medication, review e-diary, and perform treatment adherence ass essment. (Note: Enrolled subjects 
approved by [CONTACT_545833] a new site , who reside greater than [ADDRESS_714377]â€™s fam ily in order to dispense study 
medication. Assessments may be obtained remotely via telephone and treatment adherence 
assessments completed at 6-Month interval visits). 
 
Stage 2 Six-Month Visit (Month 42) 
At the Month 42 visit, the subjec t and their parent/guardian wi ll return to the study site with their 
randomized study medication. 
Information related to QoL (modi fied ATI) will be reviewed with  the subject and their 
parent/guardian and they will be asked to participate in the Qo L questionnaire. The site staff will 
confirm and document their willingness to participate in comple ting the questionnaire. Subjects can 
continue on to Stage [ADDRESS_714378] not to participate in  the completion of the QoL 
questionnaire. 
The modified ATI will be completed by [CONTACT_7071]/guardian and s ubject prior to the Investigatorâ€™s 
examination of the subject. The parent/guardian QoL questionnai re should be completed prior to the 
subject questionnaire. Study staff will verify completion of th e QoL questionnaires by [CONTACT_545834]/guardian and the subject.  
Once the modified ATI has been completed, subjects will undergo  a measurement of HR, BCVA 
measurement (distance and near), photopic pupil size measuremen t, SLE, tonometry, cycloplegic 
autorefraction, axial length, and, if possible, crystalline len s thickness. Sites will update 
concomitant medications, conduct AE assessment, dispense study medication, review e-diary, and 
perform treatment adherence assessment. 
 
End of Stage 2/End of Study (Month 48) 
At the Month 48/ end of study (EOS) visit Stage 2, the subject and their parent/guardian will return 
to the study site with their randomized study medication for an  evaluation of treatment adherence. 
The modified ATI will be completed by [CONTACT_7071]/guardian and s ubject prior to the Investigatorâ€™s 
examination of the subject. The parent/guardian QoL questionnai re should be completed prior to the 
subjectâ€™s questionnaire. Study staff will verify completion of the QoL questionnaires by [CONTACT_545834]/guardian and the subject. 
Once the modified ATI is completed, subjects will undergo a mea surement of height, weight, HR, 
BCVA measurement (distance and near), photopic pupil size measu rement, SLE, tonometry, dilated 
fundus examination, cycloplegic autorefraction, axial length, a nd, if possible, crystalline lens 
thickness. Sites will update concomitant medications, conduct A E assessment, review e-diary, and 
perform treatment adherence assessment. The site staff will uni nstall the Medidata eCOA 
application (installed on the cell phone) or retrieve the devic e provisioned by [CONTACT_545835].  
 
 
Atropi[INVESTIGATOR_545798], 0.01% and 0.02%  
Vyluma Inc., an affilia te of Nevakar Inc. 
CP-NVK002-0001(5) [ADDRESS_714379] is discontinued from study medication before the M onth 48 visit, then all Month 48 
(EOS) procedures should be performed at the visit the subject i s discontinued. 
If a subject is off study medica tion and is being followed for safety assessments then an EOS Month 
36 visit should be completed, as these subjects will not contin ue on to Stage 2.  
 
Unscheduled visits 
Unscheduled visits may occur at the Investigatorâ€™s discretion t o address any possible issues the 
subject may experience that are of concern to the subject or pa rent/guardian (e.g., blurry vision, 
pain, redness in one or both eyes). 
 
Efficacy Assessments: 
x SER error in each eye measured by [CONTACT_545823]  
x Axial length  
x Crystalline lens thickness (exploratory efficacy measurement)  
Treatment Adherence: 
Treatment adherence will be measured by [CONTACT_545836]. Throughout treatment 
(efficacy/safety portion and randomized cross-over portion), th e amount of unopened medication 
units will be recorded at each study visit. 
 
Documentation of Mode of Administration : 
At the EOS Month [ADDRESS_714380] or their parent/guardian: 
x Who administered the eyedrops to the subject during the study ( i.e., self-administered or 
administered by [CONTACT_7078]/guardian)?  
x Was there a transition in the dosing administrator? 
x If yes, at what approximate age did the transition occur? 
Safety Assessments: 
x Heart Rate 
x Monocular BCVA in each eye at 
distance and near 
x Photopic pupil size 
x Slit Lamp Exam  
x Dilated fundus examination 
x Adverse Events  
x Tonometry 
Data and Safety Monitoring Plan: 
To minimize risk and ensure the immediate safety of study subje cts, both local and systemic 
anticholinergic and other potential effects of study medication  will be measured at each visit. 
Parameters such as heart rate, mydriasis, photophobia, blurred near vision, ocular and conjunctival 
inflammation and allergic reactions to study medication will be  carefully and routinely monitored to 
assess both safety and tolerability.   
Atropi[INVESTIGATOR_545798], 0.01% and 0.02%  
Vyluma Inc., an affilia te of Nevakar Inc. 
CP-NVK002-0001(5) 14 Jun 2021 IND 130341 
 
CONFIDENTIAL AND PROPRIETARY  Page 14 of 116 All safety data will be collected and entered in the eCRF allow ing for real-time review. Medical 
review will be performed concurre ntly with Data Managementâ€™s re view of data and issue of queries 
to sites. The aim of the medical review is to monitor eligibili ty issues, assess potential protocol 
deviations and identify safety issues.  
In addition, the peer-reviewed and grey literature as well as g lobal databases of AEs from other 
atropi[INVESTIGATOR_545817]. 
Withdrawal of Subjects: 
All subjects randomized into the study will be encouraged to co mplete all study assessments 
through the Month 48 Visit (End o f Study), including subjects t hat cannot or do not wish to 
continue study treatment (withdraw consent/assent from study tr eatment but are willing to continue 
study visits). 
The following are the criteria for considering withdrawal from the study (Study discontinuation 
prior to Visit Month 48): 
x Withdrawal of subject consent/as sent to continue with study vis its. 
x If the site and/or the overall study is terminated for any reas on. 
x The Investigator considers it is in the best interest for the s ubject to leave the study. 
This may include the development of damage to the cornea (Secti on 8.5 â€“ 
Discontinuation of Study Medication). 
If a subject withdraws from the study, the reason for the subje ctâ€™s withdrawal will be recorded in 
the electronic case report form (eCRF).  
If a subject is discontinued from study medication before the M onth [ADDRESS_714381] 
should continue in the study off study medication. Subjects sho uld be encouraged to return for the 6 
Month interval visits; however, returning for the 12 Month inte rval visits is essential. Subjects 
discontinuing study medication prior to Month 36 would continue  to be seen for scheduled visits 
(at 6 Month or 12 Month intervals  as noted above) until they re ach the Month 36 interval. 
 
Criteria for Evaluation: 
Safety: 
The safety of 0.01% and 0.02% Atropi[INVESTIGATOR_545818] 
(placebo) with analysis of safety variables including ophthalmi c safety assessments (BCVA, 
photopic pupil size, SLE, dilated fundus examination, and tonom etry), HR, and AEs. 
 
Primary Efficacy Endpoint: 
The primary efficacy endpoint is the between-treatment group (A tropi[INVESTIGATOR_413242], 0.02% versus Vehicle) difference  in the proportion o f subjects who show < -0.50 D 
myopia progression (SER) at the Month 36 visit.  
The primary and all secondary endpoints comprise a fixed sequen ce set of endpoints to be tested in 
order. A 2-sided significance level of 0.05 will be adopted. 
  
Atropi[INVESTIGATOR_545798], 0.01% and 0.02%  
Vyluma Inc., an affilia te of Nevakar Inc. 
CP-NVK002-0001(5) 14 Jun 2021 IND 130341 
 
CONFIDENTIAL AND PROPRIETARY  Page 15 of 116 Secondary Efficacy Endpoints: 
The secondary efficacy endpoints consist of: 
1. Between-treatment group (Atropi[INVESTIGATOR_413202], 0.02% versus Vehicle) 
difference in the mean change fr om baseline in SER at the Month  36 visit. 
2. Between-treatment group (Atropi[INVESTIGATOR_413202], 0.01% versus Vehicle) 
difference in the proportion  of subjects who show < -0.50 D myo pia progression (SER) 
from baseline at the Month 36 visit. 
3. Between-treatment group (Atropi[INVESTIGATOR_413202], 0.01% versus Vehicle) 
difference in mean change from baseline in SER at the Month 36 visit. 
4. Between-treatment group (Atropi[INVESTIGATOR_413202], 0.02% versus Vehicle) 
difference in the mean change from baseline in axial length  at  the Month 36 visit. 
5. Between-treatment group (Atropi[INVESTIGATOR_413202], 0.01% versus Vehicle) 
difference in the mean change from baseline in axial length at the Month 36 visit. 
 Statistical Methods: 
Analysis Sets: 
Enrolled Set: All subjects enrolled. 
Safety Set: All subjects who were administered at least one dos e of study medication for a given 
stage. 
Intent-to-treat (ITT) Set: All randomized subjects for a given stage. 
Modified intent-to-treat (mITT) Set: All randomized subjects, f or a given stage, aged 6 to 10 years 
at the time of randomization in Stage 1. This will be the popul ation for the primary efficacy 
analyses. 
Per Protocol Set (PPS): All s ubjects who remain in the study th rough end of stage and have no 
major or critical protocol violations (as defined in the SAP). 
Modified Per Protocol Set (mPPS): All subjects in the PPS in ea ch stage who were aged 6 to 10 
years at the time of randomization in Stage 1. 
 
Statistical Analyses: The primary and secondary efficacy analyses will be performed u sing the mITT Set assuming data 
missing at random. 
The primary analysis and any other analysis of binary response measures will be performed using a 
mixed-effects model based on the binomial distribution using  a  logit link function.  The model will 
include subject, treatment group, visit, eye (left or right), a nd baseline age group (as randomized) 
and SER (as randomized) as independent variables and treatment group-by-visit interaction term 
included.  Random intercepts for subject and eye within subject  will be included using variance 
components and compound symmetry covariance structures, respect ively.   In addition, sensitivity 
analyses will be performed for the primary efficacy endpoint to  assess the impact of missing data.  
These sensitivity analyses will be described in the statistical  analysis plan. 
For comparisons of mean change from baseline for continuous mea sures, the analysis will be 
performed using a mixed-effects model with a random intercept.  The model will include treatment 
group, visit, eye (left or right), baseline age group (as rando mized), and baseline SER group (as 
randomized) as independent variables and the treatment group-by -visit interaction. Will be 
included.  The degrees of freedom will be determined using the Kenward-Roger approximation.  
Atropi[INVESTIGATOR_545798], 0.01% and 0.02%  
Vyluma Inc., an affilia te of Nevakar Inc. 
CP-NVK002-0001(5) [ADDRESS_714382] will be in cluded using unstructured 
covariance structures. 
Statistical Analyses (contâ€™d): 
Note, there will be 8 groups with different treatment histories  tor Year 4: 
Treatment Stage  Possible Treatment Histories 
Stage 1 (Years 1-3) 
Stage 2 (Year 4) Atropi[INVESTIGATOR_050] 0.01%  
Atropi[INVESTIGATOR_050] 0.01% Atropi[INVESTIGATOR_050] 0.01% 
Atropi[INVESTIGATOR_050] 0.02% Atropi[INVESTIGATOR_050] 0.01% 
Vehicle 
Stage 1 (Years 1-3) 
Stage 2 (Year 4) Atropi[INVESTIGATOR_050] 0.02% 
Atropi[INVESTIGATOR_050] 0.01% Atropi[INVESTIGATOR_050] 0.02% 
Atropi[INVESTIGATOR_050] 0.02% Atropi[INVESTIGATOR_050] 0.02% 
Vehicle 
Stage 1 (Years 1-3) 
Stage 2 (Year 4) Vehicle 
Atropi[INVESTIGATOR_050] 0.01% Vehicle 
Atropi[INVESTIGATOR_050] 0.02%  
For all subjects who respond in the Atropi[INVESTIGATOR_545819] 36 visit, summary statistics for the change in SER from S tage 2 baseline (Month 36 visit) 
will be presented at the Month 42 and Month 48 visits for each treatment history where subjects 
receive the same dose of Atropi[INVESTIGATOR_413202], a lower dose of Atropi[INVESTIGATOR_545807], or Vehicle.   
Summary statistics will be presented for compliance collected i n diaries, the frequency of switching 
from dosing by [CONTACT_7078]/guardian to dosing by [CONTACT_1130], and the mo dified Amblyopia Treatment Index 
by [CONTACT_545837] 4.   
Significance Level: The 0.01% and 0.02% atropi[INVESTIGATOR_545820]. The 
primary and secondary efficacy endpoints will be tested at the 5% level of significance using a 
hierarchal testing procedure in the order listed.  
 Sample Size: 
Atropi[INVESTIGATOR_413202], 0.02%: 
A Fisherâ€™s exact test with a 0.[ADDRESS_714383] 95% power to detect the 
difference between an Atropi[INVESTIGATOR_413202], 0.0 2% responder proportion of 0.25 
and a Vehicle responder proportion of 0.07 when the sample size s are 136 and 91, respectively. 
Atropi[INVESTIGATOR_413202], 0.01%: 
A Fisherâ€™s exact test with a 0.[ADDRESS_714384] 90% power to detect the 
difference between an Atropi[INVESTIGATOR_413202], 0.0 1% responder proportion of 0.25 
and a Vehicle responder proportion of 0.07 when the sample size  in each group is 91. 
Atropi[INVESTIGATOR_545798], 0.01% and 0.02%  
Vyluma Inc., an affilia te of Nevakar Inc. 
CP-NVK002-0001(5) 14 Jun 2021  IND 130341 
 
CONFIDENTIAL AND PROPRIETARY Page 17 of 116 Table 2: Schedule of Procedures 
Assessment Screening 
Baselinea Treatment Stage 1 
(Office Visits Every 3 Months and Telephone Checksa Â± 2 Weeks) Treatment Stage 2 
(Every 3 Months Â± 2 
Weeks) 
Visit Number 1 T1 T2 2 T3 3 T4 4 T5 5 6 7 8 9 10 11 12 13 14 15 16 17 
Month 0 1 2 3 4.5 6 7.5 9 10.5 12 15 18 21 24 27 30 33   36 39 42 45 48 
(EOS)b 
(EOS)b 
Informed consent/assentc X                      
Demographics/medical/ocular history X 
                     
Prior/concomitant medication X                      
Urine pregnancy testd  X                      
Re-consent/re-assente                  X  X  X  X  X  
Modified ATI questionnaires (QoL)                    Xef  Xef 
Height and weight  X         X     X     X     X  
Heart rate X     X     X  X  X  X  X  X  X 
Best-corrected visual acuityfg X     X     X  X  X  X  X  X  X 
Pupil size measurement (photopic) X     X     X  X  X  X  X  X  X 
Slit-lamp examination X     X     X  X  X  X  X  X  X 
Intraocular pressure X     X     X  X  X  X  X  X  X 
Dilated fundus examination X         X     X     X     X  
Cycloplegic autorefraction X     X     X  X  X  X  X  X  X 
Inclusion/exclusion criteria 
assessment X                      
Randomization/re-randomization 
(M 36) X                 X      
Axial length X     X     X  X  X  X  X  X  X 
Crystalline lens thickness (where 
feasible) X     X     X  X  X  X  X  X  X 
Collect study medication materials    X   X   X   X  X  X  X  X  X  X  X  X  X  X  X  X  
Atropi[INVESTIGATOR_545798], 0.01% and 0.02%  
Vyluma Inc., an affilia te of Nevakar Inc. 
CP-NVK002-0001(5) 14 Jun 2021  IND 130341 
 
CONFIDENTIAL AND PROPRIETARY Page 18 of 116 Assessment Screening 
Baselinea Treatment Stage 1 
(Office Visits Every 3 Months and Telephone Checksa Â± 2 Weeks) Treatment Stage 2 
(Every 3 Months Â± 2 
Weeks) 
Visit Number 1 T1 T2 2 T3 3 T4 4 T5 5 6 7 8 9 10 11 12 13 14 15 16 17 
Month 0 1 2 3 4.5 6 7.5 9 10.5 12 15 18 21 24 27 30 33   36 39 42 45 48 
(EOS)b 
(EOS)b 
Concomitant medication review    X   X   X   X  X  X  X  X  X  X  X  X  X  X  X  X  
Adverse event assessment X X X X X X X X X X X X X X X X X X X X X X 
Dispense study medication 
(frames/lenses)gh X   X   X   X   X  X  X  X  X  X  X  X  X  X  X  X   
Treatment adherence assessmenthi  X X X X X X X X X X X X X X X X X X X X X 
Electronic patient diary                  Xij Xjk Xjk Xjk Xkl 
Abbreviations: ATI = amblyopia treatment index, eCOA = electron ic clinical outcome assessments, EOS = end of study, QoL = qual ity of life. 
a Assessments may be obtained remotely at the end of Month [ADDRESS_714385] with protocol and treat ment adherence. Note: Enrolled  subjects approved by [CONTACT_545833] a new site, who reside greater than [ADDRESS_714386]â€™s family in order to dispense 
study medication. Assessments may be obtained remotely via tele phone and treatment adherence assessments completed at 6-Month interval visits. 
b If a subject is discontinued from study medication before the M onth [ADDRESS_714387] is discontinued.  
c Sites should complete screening/randomization/baseline procedu res and enroll subjects within 30 days from signing informed co nsent.  
d Female subjects of childbearing potential (post menarche) only.  
e All subjects are to be re-consented/re-assented at their next s tudy visit if not done at earlier visits, including subjects co mpleting an End of Study (EOS) Visit (Stage 1 â€“ Month 
36, Month 39, Month 42, Month 45, and Month 48).  
ef At Month 42 and Month 48, the modified ATI will be completed b y the parent/guardian and subject prior to the Investigatorâ€™s e xamination of the subject.  Prior to the 
examination, the site staff will ensure parent/guardian and sub ject understand the questions, by [CONTACT_545838]. After each question, the site staff will proceed to read the 
choices. The parent/guardian and subject will pi[INVESTIGATOR_545821] w hich comes closest to describing how they feel. The answer will  be entered into the database by [CONTACT_7893].  
fg Measured at distance and near.  
gh Medication dispensed by [CONTACT_3725]. Dosing to be conducted at home e ach day at bedtime. Prescription for frames/lenses will be prov ided if necessary, per criteria defined in 
Section 6.1.  
hi Treatment adherence will be verbally assessed during Telephone Check. Drug accountability and details regarding any incorrect dosing will be assessed every [ADDRESS_714388]â€™s or their parentâ€™s/guar dianâ€™s phone or Medidata provisioned device (if required), e-di ary training and Medidata eCOA support provided.  
jk The site staff will review the  electronic patient diary.  
kl The site staff will uninstall the Medidata eCOA application (i nstalled on the cell phone) or retrieve the device provisioned by [CONTACT_545826].